Following a nearly 15-year deep freeze, Stockholm has become one of the hottest European markets for biotech IPOs. The recent boom reflects a ripening of several years of investment in the early stage life sciences ecosystem that has coincided with a risk-on mentality among Sweden’s large, wealthy retail investor base. Local VCs and bankers say there are more to come.
Beginning in 2010, VCs and institutions set to work building a second-generation biotech ecosystem in Scandinavia intended to create sustainable companies that could attract global capital.
As these companies have worked toward key inflection points in the clinic, retail appetite has driven a proliferation of listings in all sectors on Sweden’s unregulated AktieTorget market. Very early stage biotechs have been among the companies that have gotten out and performed well, which has in turn translated into a bumper crop of listings on Sweden’s First North growth exchange and the main Nasdaq Stockholm market, including both IPOs and companies graduating from the AktieTorget (see “Ramping Up”).
“There’s a retail investor base that I’m not sure you have anywhere else.”
According to a November 2016 report by Stockholm VC Industrifonden, 64 pharmaceutical, medical device and digital health companies tapped one of the three public exchanges in Sweden during 2014-16; of these 33 were on the AktieTorget.
According to BioCentury’s count, five companies developing biopharmaceuticals